BACKGROUND: Although CD154 costimulation blockade prolongs allograft survival in multiple transplantation models, the underlying immunological mechanisms remain to be elucidated. METHODS AND RESULTS: We used a murine orthotopic kidney allograft (KTx) model to analyze the impact of CD154 blockade on trafficking and function of alloreactive T effector versus T regulatory cells. A single dose of MR1 Ab treatment at the time of KTx significantly improved the survival of Balb/c KTx in naïve C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<0.005), and improved graft histology, as evidenced by decreased lymphocyte infiltration and preservation of tissue architecture (days 6-8). In the early posttransplant phase, fluorescence-activated cell sorting analysis revealed preferential depression of T effector (CD8+CD25+) and relative enrichment of T-regulatory (CD4+ CD25+ CD152+) cells selectively in KTx. This pattern was further supported by intragraft gene expression analysis, which showed increased FoxP3/Tbet ratio and simultaneously decreased granzyme B/IFN-gamma levels in Ab-treated recipients. Additionally, MR1 Ab selectively up-regulated intragraft CCL17, but suppressed CXCL9/CCL5, in parallel with increased CCR4/CCR8 but unaltered CXCR3 expression. CONCLUSION: These results provide evidence, at both cellular and molecular levels, that CD154 blockade in murine KTx recipients differentially targeted T-effector and T-regulatory cell subsets by regulating intragraft induction of chemokines targeting distinct T-cell subsets.
BACKGROUND: Although CD154 costimulation blockade prolongs allograft survival in multiple transplantation models, the underlying immunological mechanisms remain to be elucidated. METHODS AND RESULTS: We used a murine orthotopic kidney allograft (KTx) model to analyze the impact of CD154 blockade on trafficking and function of alloreactive T effector versus T regulatory cells. A single dose of MR1 Ab treatment at the time of KTx significantly improved the survival of Balb/c KTx in naïve C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<0.005), and improved graft histology, as evidenced by decreased lymphocyte infiltration and preservation of tissue architecture (days 6-8). In the early posttransplant phase, fluorescence-activated cell sorting analysis revealed preferential depression of T effector (CD8+CD25+) and relative enrichment of T-regulatory (CD4+ CD25+ CD152+) cells selectively in KTx. This pattern was further supported by intragraft gene expression analysis, which showed increased FoxP3/Tbet ratio and simultaneously decreased granzyme B/IFN-gamma levels in Ab-treated recipients. Additionally, MR1 Ab selectively up-regulated intragraft CCL17, but suppressed CXCL9/CCL5, in parallel with increased CCR4/CCR8 but unaltered CXCR3 expression. CONCLUSION: These results provide evidence, at both cellular and molecular levels, that CD154 blockade in murine KTx recipients differentially targeted T-effector and T-regulatory cell subsets by regulating intragraft induction of chemokines targeting distinct T-cell subsets.
Authors: Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild Journal: Cold Spring Harb Perspect Med Date: 2013-12-01 Impact factor: 6.915
Authors: Eric A Elster; Jason S Hawksworth; Orlena Cheng; David B Leeser; Michael Ring; Douglas K Tadaki; David E Kleiner; John S Eberhardt; Trevor S Brown; Roslyn B Mannon Journal: J Mol Diagn Date: 2010-08-05 Impact factor: 5.568
Authors: Amelia R Hofstetter; Mandy L Ford; Lucy C Sullivan; Jarad J Wilson; Annette Hadley; Andrew G Brooks; Aron E Lukacher Journal: J Immunol Date: 2012-03-05 Impact factor: 5.422
Authors: J M Dodd-o; E A Lendermon; H L Miller; Q Zhong; E R John; W M Jungraithmayr; F R D'Alessio; J F McDyer Journal: Am J Transplant Date: 2011-08-09 Impact factor: 8.086
Authors: Victoria Gorbacheva; Ran Fan; Ashley Beavers; Robert L Fairchild; William M Baldwin; Anna Valujskikh Journal: J Am Soc Nephrol Date: 2019-10-09 Impact factor: 10.121
Authors: Mohamed Bikhet; Mahmoud Morsi; Hidetaka Hara; Leslie A Rhodes; Waldemar F Carlo; David Cleveland; David K C Cooper; Hayato Iwase Journal: Pediatr Transplant Date: 2020-08-26